Acorn Financial Advisory Services Inc. ADV Sells 1,427 Shares of Collegium Pharmaceutical, Inc. $COLL

Acorn Financial Advisory Services Inc. ADV lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 37,232 shares of the specialty pharmaceutical company’s stock after selling 1,427 shares during the period. Acorn Financial Advisory Services Inc. ADV owned about 0.12% of Collegium Pharmaceutical worth $1,101,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in Collegium Pharmaceutical by 4.5% in the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company’s stock worth $326,000 after buying an additional 477 shares during the period. SummerHaven Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 2.1% during the 2nd quarter. SummerHaven Investment Management LLC now owns 24,868 shares of the specialty pharmaceutical company’s stock valued at $735,000 after purchasing an additional 514 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Collegium Pharmaceutical by 4.2% during the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company’s stock valued at $426,000 after purchasing an additional 578 shares during the last quarter. Uniplan Investment Counsel Inc. boosted its holdings in shares of Collegium Pharmaceutical by 0.6% during the 1st quarter. Uniplan Investment Counsel Inc. now owns 142,801 shares of the specialty pharmaceutical company’s stock valued at $4,263,000 after purchasing an additional 797 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after purchasing an additional 825 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL opened at $32.04 on Tuesday. The firm has a market cap of $1.01 billion, a P/E ratio of 30.81 and a beta of 0.65. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $39.95. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. The stock has a 50-day moving average of $36.21 and a 200 day moving average of $31.69.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The company had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical announced that its board has authorized a stock buyback plan on Monday, July 7th that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the specialty pharmaceutical company to buy up to 15.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 17,478 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $38.42, for a total value of $671,504.76. Following the completion of the sale, the executive vice president owned 70,264 shares of the company’s stock, valued at $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gino Santini sold 5,405 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $37.19, for a total transaction of $201,011.95. Following the completion of the sale, the director directly owned 95,042 shares of the company’s stock, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,792 shares of company stock worth $2,084,207. Insiders own 2.51% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on COLL shares. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 24th. HC Wainwright raised shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective for the company in a report on Monday, August 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $42.33.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.